1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 52 (Search time: 0.004 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2017Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemiaSopper, S.; Mustjoki, S.; White, D.; Hughes, T.; Valent, P.; Burchert, A.; Gjertsen, B.; Gastl, G.; Baldauf, M.; Trajanoski, Z.; Giles, F.; Hochhaus, A.; Ernst, T.; Schenk, T.; Janssen, J.; Ossenkoppele, G.; Porkka, K.; Wolf, D.
2014Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyHughes, T.; Hochhaus, A.; Kantarjian, H.; Cervantes, F.; Guilhot, F.; Niederwieser, D.; Le Coutre, P.; Rosti, G.; Ossenkoppele, G.; Lobo, C.; Shibayama, H.; Fan, X.; Menssen, H.; Kemp, C.; Larson, R.; Saglio, G.
2016TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapyNievergall, E.; Reynolds, J.; Kok, C.; Watkins, D.; Biondo, M.; Busfield, S.; Vairo, G.; Fuller, K.; Erber, W.; Sadras, T.; Grose, R.; Yeung, D.; Lopez, A.; Hiwase, D.; Hughes, T.; White, D.
2016Chronic myeloid leukemia: reminiscences and dreamsMughal, T.; Radich, J.; Deininger, M.; Apperley, J.; Hughes, T.; Harrison, C.; Gambacorti-Passerini, C.; Saglio, G.; Cortes, J.; Daley, G.
2014Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinibEadie, L.; Hughes, T.; White, D.
2013Which TKI? An embarrassment of riches for chronic myeloid leukemia patientsHughes, T.; White, D.
2015A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemiaBartley, P.; Latham, S.; Budgen, B.; Ross, D.; Hughes, E.; Branford, S.; White, D.; Hughes, T.; Morley, A.
2014Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cellsNievergall, E.; Ramshaw, H.; Yong, A.; Biondo, M.; Busfield, S.; Vairo, G.; Lopez, A.; Hughes, T.; White, D.; Hiwase, D.
2013Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLBranford, S.; Yeung, D.; Ross, D.; Prime, J.; Field, C.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Sullivan, B.; Briggs, N.; Hertzberg, M.; Seymour, J.; Reynolds, J.; Hughes, T.
2013Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.

Discover